Create Medicines received Human Research Ethics Committee approval in Australia to initiate a first-in-human study of CRT-402, its lead in vivo CAR T candidate for autoimmune diseases. The approval enables the company to start the early clinical evaluation, moving the program closer to IND-enabling pathways and initial human safety and feasibility data. CRT-402 is positioned as an in vivo immune-cell engineering approach, reflecting the industry’s continuing preference for simplifying logistics relative to ex vivo CAR-T manufacturing. For Australia-based development teams and trial networks, the ethics approval is the first clinical milestone enabling recruitment and protocol activation. The company’s next steps will be tightly linked to early safety signals, expression durability, and immunogenicity monitoring, which typically define how quickly in vivo platforms can scale into dose-escalation and expansion cohorts.